Search

1121 Result(s)
Sort by

clinical_collaboration_with_Mirati

clinical_collaboration_with_Mirati

Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Partnership with Precision Health Research, Singapore

Partnership with Precision Health Research, Singapore

Boehringer Ingelheim joins forces with Precision Health Research, Singapore with the aim of transforming healthcare and improving patient outcomes in Singapore and beyond.
Listen to the sounds disrupting farms worldwide

Listen to the sounds disrupting farms worldwide

A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
New data for nintedanib in children with fibrosing ILD

New data for nintedanib in children with fibrosing ILD

InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Five facts everyone should know about heartworms

Five facts everyone should know about heartworms

Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Our transformative team culture

Our transformative team culture

The immunology team is grounded in three key elements: Curiosity, creativity and courage. Hear about the culture at Boehringer Ingelheim.
FDA approval NexGard PLUS for dogs

FDA approval NexGard PLUS for dogs

Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Green Chemistry

Green Chemistry

Green Chemistry is critical for us as it balance the long-term sustainability of business, society, and the environment.
Ruminant parasite control in a nutshell

Ruminant parasite control in a nutshell

An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
Matthias Muenks

Matthias Muenks

Matthias Muenks, Global Engineering Process and Data Manager, speaks about our innovation and culture.
Avian influenza prevention at the source

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.